Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to document the activity and safety of single agent amrubicin,
amrubicin combined with cisplatin, and etoposide combined with cisplatin as first-line
treatment in extensive disease small cell lung cancer.